Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-escalation Study of Intermittent, Once Weekly, and Continuous Daily Oral OSI-027 Dosing in Patients With Advanced Solid Tumors or Lymphoma

NCT00698243 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00698243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00698243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-escalation Study of Intermittent, Once Weekly, and Continuous Daily Oral OSI-027 Dosing in Patients With Advanced Solid Tumors or Lymphoma
Lead sponsor
Astellas Pharma Inc
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2008
Completion date
February 28, 2013
Enrollment
128 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

any solid tumor or lymphoma